Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Title
Intervention Indication Therapeutic Area Year Actions
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406) Ovarian cancer Female Reproductive Cancer 2018 View  |  Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2019 View  |  Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2021 View  |  Download
Ipatasertib in addition to paclitaxel for locally advanced or metastatic triple-negative breast cancer Ipatasertib (GDC-0068; RG7440) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2020 View  |  Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317) Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Veliparib in addition to carboplatin and paclitaxel for epithelial ovarian, fallopian tube, or primary peritoneal cancer Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Breast cancer Breast Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications